[Pubmed] Mortality in generalized myasthenia gravis among Medicare beneficiaries in the United States
Posté : 06 oct. 2026 12:00
Curr Med Res Opin. 2026 Oct 5:1-10. doi: 10.1080/03007995.2026.2740307. Online ahead of print.
ABSTRACT
BACKGROUND: Data on mortality risk and its predictors among elderly patients with generalized myasthenia gravis (gMG) in the United States remain limited.
METHODS: A prevalent cohort of Medicare Fee-for-Service beneficiaries with gMG and those without MG were identified using data from 01/2018 to 12/2023. Patients without MG were matched 10:1 to the gMG cohort on age and index year. Cohorts were weighted using overlap propensity scores on demographic and clinical characteristics. Mortality was assessed using Kaplan-Meier and Cox proportional hazards models from the index date (gMG cohort: random gMG-related visit; non-MG cohort: random medical visit) until death, end of data, or loss of eligibility. Predictors of all-cause mortality were evaluated among the gMG cohort using multivariable Cox regression.
RESULTS: The study included 37,321 patients with gMG and 373,210 patients without MG (mean age: 74 years; 47% female). Patients with gMG had 8% higher mortality risk at 12 months and 7% higher risk at 24 and 36 months than those without MG (all p < 0.001). Among patients with gMG, mortality risk increased with older age (by 430% for ages ≥85 vs
Source: https://pubmed.ncbi.nlm.nih.gov/4283466 ... 7&v=2.20.1